Bharat Biotech’s typhoid vaccine hailed as success in Oxford study
Indian pharmaceutical Bharat Biotech’s typhoid vaccine, Typbar-TCV has been marked as a success by a study conducted in Oxford University. Foremost amongst the findings is that the Typbar-TCV vaccine is safe to use in children aged under two. This is of huge significance as current widely used vi-ps typhoid vaccine cannot be used in children …
Bharat Biotech’s typhoid vaccine hailed as success in Oxford study Read More »